QUICK ANSWER · AEO / GEO
LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.
Read original excerpts (Thai / mixed language)
- Host-defence peptide ≠ approved antibiotic; ไม่ยืนยันการรักษาการติดเชื้อทุกชนิดหรือ systemic immune boosting
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
FAQ · ANSWER ENGINE
Frequently asked questions
What is LL-37?
LL-37 is described pharmacologically as Cathelicidin host-defence peptide. LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety.
Does LL-37 have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is LL-37 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.